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Abstract
A number of inflammatory lung diseases have abnormally low glutathione (GSH) levels in the airway fluids. Lung
macrophages are common mediators of inflammation, make up the majority of cells that are found in the airway epithelial
lining fluid (ELF), and are commonly elevated in many lung diseases. Several animal models with altered ELF GSH levels are
associated with similar alterations in the intracellular GSH levels of bronchoalveolar lavage (BAL) cells. The possible
mechanisms and outcomes for this association between ELF GSH levels and intracellular BAL cell GSH are unknown. To
investigate these issues, macrophages were grown in media supplemented with 500 mM GSH. GSH supplementation
resulted in a 2–3 fold increase in macrophage intracellular GSH levels. The increase in macrophage intracellular GSH levels
was associated with a significant reduction in NF-kB nuclear translocation and tumor necrosis factor a (TNFa) release upon
LPS stimulation. Furthermore, co-treatment of macrophages with GSH and inhibitors of GSH breakdown or synthesis did not
block GSH accumulation. In contrast, treatment with cytochalasin D, an inhibitor of actin dependent endocytosis, and
amiloride, an inhibitor of macropinocytosis blocked, at least in part, GSH uptake. Furthermore, using two cigarette smoke
exposure paradigms that result in two different GSH levels in the ELF and thus in the BAL cells resulted in modulation of
cytokine release when stimulated with LPS ex vivo. These data suggest that macrophages are able to utilize extracellular
GSH which can then modulate inflammatory signaling in response to proinflammatory stimuli. This data also suggests the
lung can modulate inflammatory responses triggered by proinflammatory stimuli by altering ELF GSH levels and may help
explain the dysregulated inflammation associated with lung diseases that have low ELF GSH levels.
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Introduction
The epithelial lining fluid (ELF) of the lung is a heterogeneous
mixture of cells, proteins, and low molecular weight antioxidants
[1,2]. The ELF functions as a barrier and sensor for inhaled agents
and pathogens [3]. The lung has developed adaptive mechanisms
in which antioxidants, of which glutathione (GSH) is highly
abundant, can be raised in the ELF in response to stressors [4,5].
Additionally there are leukocytes that reside in the ELF and
function to clear debris or pathogens that may deposit in the
airways. Alveolar macrophages (AMs) make up between 88–95%
of all the types of leukocytes typically recovered in bronchoalveolar
lavage fluid (BALF) under normal conditions [6].
There are several lung diseases that have been shown to have
characteristically low ELF GSH levels. These lung disorders
include chronic obstructive pulmonary disease (COPD), acute
respiratory distress syndrome (ARDS), cystic fibrosis (CF), and
although not typically thought of as a disease, aging [7,8,9]. The
decrease in ELF GSH (up to 90%) leaves these individuals
incredibly susceptible to oxidant or pathogen mediated lung
damage. Under conditions of decreased GSH, patients typically
exhibit decreased pathogen clearance leading to chronic inflam-
mation [10]. This is especially important since many of these lung
disease have high levels of airway inflammation and recurrent
exacerbations [11].
Exaggerated airway inflammation is a hallmark of COPD [12].
In models of COPD, the proinflammatory cytokine tumor necrosis
factor alpha (TNFa) has been shown to be responsible for roughly
70% of the morphological changes associated with smoking, a
major risk factor for COPD [13]. Additionally, in models of aging,
ELF GSH levels have been shown to be inversely correlated with
TNFa levels [14]. Furthermore, GSH has been directly linked
with TNFa through the depletion of GSH with buthionine
sulfoximine (BSO) resulting in the increase in airway TNFa levels
[14].
One potential consequence of changes in ELF GSH may
involve the AMs that reside in the ELF. When activated by a
stimulus like cigarette smoke or lipopolysaccharide (LPS),
macrophages produce and release TNFa and AMs have been
shown to be highly activated when ELF GSH levels are low
[15,16]. However the mechanisms by which alveolar macrophages
sense and respond to changes in ELF GSH are unknown.
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extracellular GSH at physiologically relevant levels seen in the
ELF and GSH synthesis dependant and independent pathways
were examined. Additionally, the effect of altering GSH levels on
macrophage TNFa release was assessed. These studies suggest that
macrophages can uptake extracellular GSH by endocytosis and
thereby alter their intracellular GSH levels resulting in suppressed
cytokine response to inflammatory stimuli. These studies suggest a
physiological role for maintaining high levels of ELF GSH in
response to inflammatory stimuli as well as suggest a mechanism
for the exaggerated inflammation seen in the number of lung
disease states with low ELF GSH.
Methods
Animals and cells lines
C57B/6 mice were obtained from Jackson laboratory and aged
mice were either obtained from our in house animal colony or the
National Institute on Aging. Male 2 to 4 month old CFTR
transgenic mice that posses the S480X truncation mutation with
gut corrected recombinant human CFTR were obtained from our
in house colony as previously reported [17]. All animal procedures
were approved by the National Jewish Health IACUC committee.
The murine macrophage like J774 cell line was obtained from the
American Type Culture Collection and maintained in DMEM
with 10% FBS and antibiotics.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed using two 750 mL
rinses of cold isotonic potassium phosphate solution. BAL cells
were removed by centrifugation and analyzed for GSH. The
dilution of the ELF was calculated by measuring urea in both the
BALF and plasma as previously reported [14].
Cigarette smoke exposure and L-Buthionine-sulfoximine
(BSO) treatment
The mice were exposed to cigarette smoke (CS) from Kentucky
reference cigarette 3R4F (University of Kentucky) for 2 h and
sacrificed immediately following the exposure or for 24 h which
includes 5 h CS exposure and 19 h rest period using a TE-10
cigarette smoke exposure system (Teague Enterprises). The
average particulate matter was 120 mg/m
3 and carbon monoxide
averaged 350 ppm. For the pharmacologic manipulation of ELF
GSH levels mice were administered BSO (Sigma) in the drinking
water at a final concentration of 20 mM for a total of 11 days as
previously reported [14].
Primary alveolar macrophage (AM) isolation
Primary AM were isolated and pooled from the airways of 5–10
mice. Mice were given an overdose of pentobarbital and their
tracheas were cannulated. BAL was performed four times using
1 mL of room temperature PBS. The recovered BALF was pooled
and the centrifuged to pellet the lavage cells. The BAL cell pellet
was resuspended in warm DMEM with 10% FBS and antibiotics
and cultured in 96-well plates at a density of at least 70,000 cells
per well. An aliquot of BAL cells was used to prepare cytospin
slides for differential cell counts. Over 95% of the BAL cells
recovered were AMs.
Measurement of glutathione
Total glutathione (GSH) was measured spectrophotometrically
as previously reported [14]. In short, 20 mL sample or standard in
triplicate was incubated with 100 mL 5,59-dithiobis(2-nitrobenze-
noic acid) and glutathione reductase solution. The reaction was
started by the addition of 50 mL NADPH and read at 412 nm for
5 min using a SpecraMax 340PC microplate reader (Molecular
Devices). Intracellular levels are normalized to protein content.
Tumor Necrosis Factor-a release
Pseudomonas LPS at a final concentration of 10 or 50 ng/mL
was used to stimulate macrophage TNFa release. Tumor necrosis
factor alpha (TNFa), a common proinflammatory cytokine, was
measured in the cell culture media after 2 h stimulation with
lipopolysaccharide (LPS). TNFa was measured by ELISA (BD
Biosciences) according to manufactures recommendations.
Glutathione supplementation
Cell culture media was supplemented with reduced glutathione
at a final concentration of 500 mM. For the cell line, GSH was
added to the media for 24 hours and only 2 hours for the primary
AM before the assessment of changes in intracellular GSH levels.
A stock fluorescent labeled GSH (Fl-GSH) solution was prepared
by incubating GSH with monobromobimane at a 4:1 ratio and
then diluting to the desired concentration in the culture media,
which should result in only a fraction of the total GSH that was
added to the media as being fluorescent. For the in vivo
administration of Fl-GSH, a 4 mM stock concentration of GSH
was incubated with 3 mM monobromobimane and 20 mL was
intra-tracheal administered for 2 h. Fluorescently labeled GSH
was visualized in BAL cell cytospin preparations using an inverted
EvoS fluorescent microscope (Advanced Microscopy Group) and
quantified in the ELF and recovered macrophages using HPLC
with fluorescent detection as previously described [17].
Glutathione attenuation of TNFa release
Cells were cultured in media with or without GSH supplemen-
tation for 24 h to raise intracellular GSH levels. Old media was
removed and fresh media was added with or without GSH and
LPS at 10 or 50 ng/mL for a total of 2 h. Media was then
removed and any non adherent cells were removed by
centrifugation. TNFa in the media was then measured by ELISA.
For primary AM, cells were freshly isolated and plated in media
with or without GSH. LPS (10 or 50 ng/mL) was added
immediately and the media was then removed after 2 h and
TNFa analyzed by ELISA.
Examination of GSH uptake pathway
To elucidate the uptake mechanism of GSH, inhibitors of
several pathways were used. Buthionine-sulfoximine (BSO), an
inhibitor of GSH synthesis, and acivicin, an inhibitor of GSH
breakdown, were used at a final concentration of 100 mM
concurrently with GSH in the media. Cytochalasin D, an inhibitor
of endocytosis through the inhibition of actin polymerization, was
used at a final concentration of 1 mM. Additionally more specific
inhibitors such as amiloride (125 mM) for macropinocytosis, and
polyinositol acid and amantadine (100 mM each) for receptor
mediated pathways were also examined.
Western blotting for protein expression
Nuclear and cytosolic fractions were obtained using the NE-
PER nuclear isolation kit (Thermo) according to manufactures
protocol. Total protein (10 mg) was loaded and run on a
polyacrylamide gel and transferred to PVDF membrane. Mem-
branes were blocked with 5% BSA and probed with primary
antibodies for NF-kB p65 subunit at 1:500 (Abcam) for 2.5 h at
room temperature. The blots were then washed three times with
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with the secondary peroxidase conjugated goat anti rabbit
antibody (Abcam) at a dilution of 1:25,000 for 30 min at room
temperature. Proteins were visualized using ECL plus western
blotting detection reagents (GE healthcare) according to manu-
factures protocol.
Statistical analysis
All data is represented as the mean 6 standard error of the
mean. Significance was set at a p,0.05. An unpaired t test or two-
way analysis of variance (ANOVA) was performed with a
bonferroni post test using Prism 5 software (GraphPad).
Results
A correlation between bronchoalveolar lavage cell GSH
levels and ELF GSH levels
The bronchoalveolar lavage (BAL) cells, which are predomi-
nately AMs, reside within the ELF, and thus many of the nutrients
for them to survive are derived from the ELF. GSH is one of the
most abundant antioxidants in the ELF and we hypothesized that
the AMs may be able to utilize this large pool of GSH. In mouse
models that have either normal, increased, or decreased ELF GSH
we observed similar changes in the intracellular GSH levels from
the recovered AM (Table 1). There is a strong positive correlation
between AM GSH and ELF GSH levels (r=0.72, p,0.0001).
Under normal conditions the ELF GSH is roughly 96 mM and the
AM GSH is 6.3 nmol/mg. When the ELF GSH increases to
272 mM in response to CS the AM GSH increased to 9.9 nmol/
mg. Consequently, when very acute cigarette smoke exposures are
performed, with little rest time between the exposure and sampling
of the ELF, GSH levels are decreased to roughly 21 mM and
1.22 nmol/mg for the ELF and BAL cells respectively. Further-
more, in other animal models when the ELF GSH falls by roughly
half either due to aging, alterations in transport through mutant
CFTR, or chronic BSO treatment, the AM GSH falls to roughly
half of the normal level as well.
Macrophage utilization of extracellular GSH
Based on the fact that there is a significant correlation between
ELF GSH and macrophage GSH, we sought to examine whether
macrophages can actually utilize extracellular GSH. Two different
cell types, a murine derived macrophage cell line J774 (Fig. 1A),
and primary mouse AM (Fig. 1B) were grown either in normal
media or media supplemented with 500 mM GSH. 500 mM GSH
was used because it is a physiologically relevant level that can
easily be reached in the ELF in various times of stress including
smoking [14] and infection [18]. When both the J774 and primary
AM are grown in high GSH media the intracellular GSH levels
were significantly higher than in cells grown in normal media.
Intracellular GSH status alters inflammatory cytokine
release
GSH has been shown to be a potent regulator of proinflamma-
torycytokine release invitroand invivo [14,19]. Additionally,lower
GSH in the airways has previously been associated with excess
macrophage activation, which can lead to proinflammatory
cytokine release [14]. To confirm that GSH has a similar anti-
inflammatory effect in macrophages as has been previously shown,
both the J774 (Fig. 2A) and primary AM (Fig. 2B) were grown in
either normal or GSH containing media and stimulated with 10 or
50 ng/mL LPS for 2 h, after which TNFa release was measured.
There was a dose dependant increase in TNFa in the J774 (Fig. 2A)
cells after LPS stimulation, while GSH significantly attenuated the
TNFa release. Similarly, GSH also significantly attenuate the LPS
mediated TNFa at both doses of LPS in the primary AM (Fig. 2B).
In contrast to the cell line, the primary AM cells had a much higher
TNFa response to the high dose of LPS. In both cell types the
extracellular GSH supplementation blocked any increase in TNFa
with 10 ng/mL LPS dose. LPS itself did not have any effect on
intracellular GSH levels or uptake (data not shown). To confirm
that GSH is having anti-inflammatory effects, nuclear translocation
Table 1. Correlation between mouse ELF GSH and Alveolar
Macrophage GSH.*
ELF GSH (mM)
Alveolar Macrophage
GSH (nmol/mg)
Wild Type 96.661.57 6.360.75
2 h Cigarette smoke 21.5268.11 1.2260.32
24 h Cigarette smoke 615.4682.47 11.5460.42
recovery
Aging (26 months) 46.663.96 3.360.84
CFTR KO 52.065.77 2.561.04
Chronic BSO 49.565.73 2.960.23
*Data represented as mean 6standard error, r=0.72, p,0.0001.
doi:10.1371/journal.pone.0025704.t001
Figure 1. Extracellular GSH alters intracellular levels. J774 (A), or
primary alveolar macrophages (B) were grown in media supplemented
with or without 500 mM GSH and intracellular GSH levels were
measured. Data represented as mean 6 SEM, with ***p,0.001.
doi:10.1371/journal.pone.0025704.g001
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stimulation with LPS in the presence or absence of GSH (Fig. 2C).
Confirming the results of the cytokine analysis, the supplementation
of GSH blocked the nuclear translocation of NF-kB.
Intracellular GSH accumulation is dependent on
macropinocytosis
To determine how macrophages can utilize the available GSH
in the extracellular compartment various pathways of GSH
utilization, including synthesis, breakdown, transport, and endo-
cytosis were examined in the J774 cells (Fig. 3). Buthionine
sulfoximine (BSO) is a potent inhibiter of c-glutamylcysteine
ligase, the rate limiting enzyme involved in GSH synthesis. c-
Glutamyl transferase is the only known enzyme that breaks down
GSH, which can be inhibited with acivicin, and previous reports
have shown that intracellular transport of GSH can be inhibited
using methionine [20]. Inhibiting GSH synthesis with BSO did not
alter the intracellular uptake of GSH compared to the uptake in
untreated cells. Furthermore, the inhibition of either breakdown or
transport did not affect the uptake of GSH. Conversely,
cytochalasin D, a broad inhibitor of endocyotosis was able to
completely block the uptake of GSH, suggesting that the increase
in intracellular GSH is not through other more common pathways
but rather through an endocytosis uptake mechanism. To further
narrow down the potential endocytosis mechanism amiloride, an
inhibitor of macropinocytosis, was used and shown to inhibit
nearly half of the GSH uptake, strongly suggesting that the uptake
mechanism is macropinocytosis. Furthermore, polyinositol acid
and amantadine, two inhibitors of receptor mediated endocytosis
did not block the GSH uptake (data not shown). While the most
likely uptake mechanism is macropinocytosis, in comparison to
amiloride, cytochalasin D is a much more potent inhibitor of GSH
uptake, therefore for further inhibitory studies the more potent
inhibitor was used.
Macropinocytosis is required to attenuate inflammatory
responses
To further show that the GSH administered in the extracellular
space is responsible for the intracellular increases, fluorescent
labeled GSH was used as a probe for the macropinocytosis of
GSH. Cells were incubated with a combination of unlabelled and
fluorescent labeled GSH in a ratio of 4:1 and the GSH uptake was
visualized after 24 h. In contrast to the control cells (Fig. 4A) those
Figure 2. GSH supplementation alters inflammatory cytokine
release. The J774 (A) and primary AM (B) were grown in media with or
without 500 mM GSH and treated with LPS for 2 hours. TNFa release
was analyzed in the media by ELISA. J774 nuclear fractions were
examined for the nuclear translocation of the p65 subunit of NF-kB (C),
HDAC used as a protein loading control with the ratio of p65 to HDAC
area density listed below. Data represented as mean 6 SEM, with
***p,0.001 compared between PBS and GSH.
doi:10.1371/journal.pone.0025704.g002
Figure 3. Uptake of GSH is through macropinocytosis. J774 cells
were grown in media supplemented with 500 mM GSH either containing
buthionine sulfoxime (BSO), acivicin, or methionine to inhibit synthesis,
breakdown or transport ofGSH, respectively(A). CytochalasinD wasused
as an inhibitor of endocytosis and amiloride was used as more specific
inhibitor of macropinocytosis. Data represented as mean 6 SEM, with
*p,0.05, ***p,0.001 compared to control.
doi:10.1371/journal.pone.0025704.g003
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fluorescence which could then be blocked using cytochalasin D
(Fig. 4C). It is interesting to note that not all cells had increased
fluorescent labeling suggesting that rates of macropinocytosis must
vary among the cells.
To elucidate the role of extracellular GSH versus intracellular
GSH, cytochalasin D was used to block the uptake of extracellular
GSH in J774 cells and the LPS induced TNFa release was
examined (Fig. 4D). The cells were grown in normal or GSH
containing media with cytochalasin D to block the uptake and
then stimulated with LPS for 2 h. While the cells cultured in GSH
supplemented media alone sho wed an attenuation of LPS
stimulated TNFa release, cytochalasin D completely blocked the
anti-inflammatory effect of GSH with TNFa levels comparable to
LPS stimulated cells alone, cytochalasin D alone did not have any
effect on TNFa release (data not shown). Taken together these
data show that the extracellular administered GSH is in fact being
internalized which is required for the attenuation of cytokine
release and that the anti-inflammatory effect of GSH is due
entirely to the intracellular status, not the extracellular levels.
Uptake of exogenously administered GSH in vivo
To definitively determine whether the macropinocytosis of
GSH occurs in vivo, Fl-GSH was administered intratracheally and
examined after a period of 2 h. Fl-GSH (20 mL) was administered
to each mouse based on the assumption that the ELF is roughly
100 mL, theoretically resulting in roughly a 500 mM concentration
of Fl-GSH in the ELF. The Fl-GSH was visualized using
fluorescent microscopy revealing a cellular accumulation of Fl-
GSH (Fig. 5B) compared with control BAL cells (Fig. 5A) which do
not contain any fluorescence. The unique ability to detect the Fl-
GSH over endogenous GSH was achieved by quantifying the
change in fluorescence in both the ELF and BAL cells (Fig. 5C) by
HPLC with fluorometric detection. The concentration of Fl-GSH
in the ELF resulted in roughly 575 mM and 84 nmol/mg in the
BAL cell lysates. It should be noted that this is only the amount of
the exogenously administered Fl-GSH in the ELF and BAL cells,
since it does not take into account the endogenous non-fluorescent
GSH levels. This data shows that when exogenous GSH is
administered it is readily taken up by the BAL cells which are
predominately AMs.
GSH status with two cigarette smoke exposure
conditions results in altered cytokine response
COPD is one of the most prevalent lung diseases characterized
by exaggerated lung inflammation, but it also has been shown to
have altered ELF GSH levels [5]. In relation to the previous data
shown, AMs may be major mediators of inflammation with CS,
the primary cause of COPD. Therefore, two different CS exposure
paradigms were examined; an acute 2 h smoke exposure with no
rest time before sampling of the ELF and a 24 h exposure with the
mice exposed to CS for 5 h and allowed to rest for a complete
19 h before sampling of the ELF. With very short periods of CS,
GSH can become depleted and we have established that this
occurs within 2 h (data not shown); furthermore, with a slightly
longer exposure it is well known the CS will induce adaptive
responses, including GSH synthesis, resulting in increased ELF
GSH [14]. We utilized both exposure paradigms to establish two
very different ELF environment, one in which the ELF GSH is
depleted down to 21 mM after the 2 h exposure and one in which
the ELF GSH is increased to roughly 425 mM after a 24 h
exposure (Fig. 6). As was shown in Table 1, the BAL cell GSH,
which is in the intracellular compartment, also corresponds with
the either increase or decrease in ELF GSH. With the 2 h
Figure 4. Anti-inflammatory effects of GSH are dependent on macropinocytosis. Brighfield images of control (A), fluorescent labeled GSH
(Fl-GSH) (B) or Fl-GSH with cytochalasin D (C) provide further evidence for the direct uptake of extracellular GSH. Furthermore, LPS induced TNFa
release was examined after supplementation with GSH and/or cytochalasin D to block that uptake (D). Data represented as mean 6 SEM, with
***p,0.001 compared to either LPS only.
doi:10.1371/journal.pone.0025704.g004
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the BAL cell GSH is increased to roughly 11.5 nmol/mg after the
full 24 h exposure.
These two CS exposure paradigms were utilized to determine
whether altered extracellular GSH levels have an effect on
macrophage cytokine production in an ex vivo model. Primary
AM were isolated from mice either exposed to CS for 2 or 24 h
and incubated with LPS in culture media for 2 h, after which
TNFa release was examined (Fig. 7). The AM that were in the low
GSH ELF after the 2 h exposure had a higher TNFa response to
LPS than the cells that had resided in the high ELF GSH after the
24 h exposure. Neither of the cell conditions had altered basal
levels of TNFa release. This data shows that the utilization of
GSH to modulate inflammatory cytokine release can occur in vivo
and may have a significant impact on inflammatory lung diseases
that have characteristically low ELF GSH levels.
Discussion
These studies demonstrate a strong association between the
extracellular (ELF) and intracellular GSH levels in AMs. In
addition, these studies provide data that suggests macrophages can
utilize extracellular GSH to supplement intracellular GSH levels
via macropinocytosis that redox modulates NF-kB signaling
involved in inflammatory responses to triggers such as LPS. This
evidence supports a novel mechanism by which extracellular GSH
status modulates AM response to inflammatory stimuli and
provides a role for extracellular GSH as a negative feedback loop
for lung inflammation.
Figure 5. In vivo uptake of fluorescent labeled GSH. Fluorescent
labeled GSH (Fl-GSH) was administered intratracheally and examined
after a period of 2 h. Representative image of BAL cells recovered from
control (A) and Fl-GSH (B) administered mice. Quantization of resulting
Fl-GSH concentrations 2 h after administration (C), control samples
contain no detectable fluorescence.
doi:10.1371/journal.pone.0025704.g005
Figure 6. Different smoke exposure paradigms result in
different GSH levels. Mice were exposed to acute 2 h cigarette
smoke (CS) exposure with little rest before sampling of the ELF and BAL
cell GSH which resulted in depleted GSH levels. However, after a 24 h
exposure which includes a rest period there is a full adaptive response
with elevated ELF and BAL cell GSH levels. Data represented as mean 6
SEM, with *p,0.05, ***p,0.001 compared to either ELF or BAL cell
control.
doi:10.1371/journal.pone.0025704.g006
Figure 7. Altered GSH status in the airways results in different
cytokine response to LPS. Alveolar macrophages were obtained
from mice sampled immediately after a 2 h (closed bars) cigarette
smoke (CS) exposure or 24 h (open bars) recovery from CS exposure
and treated with LPS for 2 h. TNFa release was measured by ELISA. Data
represented as mean 6 SEM, with ***p,0.001 compared between 2 h
CS and 1 d CS.
doi:10.1371/journal.pone.0025704.g007
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correlate with the amount of TNFa secreted in the airways [14].
Additionally, there is an increase in activation state of the AM
from mice with low ELF GSH in response to CS compared to
those from mice with higher ELF GSH. In the present study, the
maintenance of macrophage intracellular GSH levels seems to be
partly dependent on the ELF GSH pool which the AM can access
by endocytosis. The utilization of extracellular GSH by the AM is
interesting since they posses all the necessary enzymes and
cofactors for de novo synthesis of GSH. One possibility is that in
contrast to some other apical fluids, like plasma, the ELF contains
rather low levels of cysteine/cystine [21], thus while the AM do
have the ability to synthesize GSH, the constitutive amino acids
may be limiting. There is also some evidence that inflammatory
cells may not express the enzymes needed for GSH synthesis to the
same degree as other cell types, and low enzyme expression limits
the de novo synthesis ability [22,23]. The lung may use this
auxotrophy as a means to regulate inflammatory responses to
environmental stimuli.
Macrophages make up the majority of the cell types found in the
alveolar spaces under normal conditions. Because of the large
population of macrophages compared to other leukocytes like
neutrophils, the macrophages are most likely a major mediator of
inflammatory signaling in the lung [15,24,25,26]. While previous
reports have shown that thiol status can alter cytokine release [27],
this is the first report to link it with a potential in vivo consequence.
Macrophages are well known scavengers of particles, viruses, and
bacteria within the lung, thus they have specialized mechanisms
such as phagocytosis to achieve these functions. There are many
different classes of endocytosis including receptor mediated,
receptor independent, pinocytosis, and macropinocytosis just to
name a few [28]. Due to the abundance of GSH in the ELF, it
does not seem conceivable that receptor mediated pathways would
be necessary for the uptake of GSH, therefore the uptake is most
likely a generalized sampling of the extracellular fluid. In the
present study, the uptake of GSH is blocked by cytochalasin D, an
inhibitor of actin polymerization, indicating that pinocytosis can
be ruled out since actin is not required for the uptake of small
particles [28]. However, an uptake mechanism of slightly larger
particles up to 2 mm in size, which does require actin is
macropinocytosis [29]. Since GSH was observed to be taken up,
and it is well under the 2 mm size of vesicles that form, it stands to
reason that the mechanism of endocytosis is macropinocytosis.
Amiloride has been reported to be an inhibitor of macropinocy-
tosis [30], however it did not completely block GSH uptake.
Amiloride works primarily by blocking sodium channels and
altering intracellular pH affecting the activity of certain kinases
involved so it is conceivable that other effects not related to the
inhibition of macropinocytosis could be involved. Regardless,
cytochalasin D did completely inhibit uptake which strongly
suggests the uptake mechanism is macropinocytosis.
The ability for cytochalasin D to block the GSH mediated
attenuation of cytokine release shows that it is the intracellular
thiol status of the macrophages that is important for the
modulation of inflammation. Any of the extracellular effects of
GSH, such as the potential to alter receptors or binding to the
membrane can be ruled out since blocking the uptake of GSH
with cytochalasin D resulted in a similar TNFa level as LPS alone.
Furthermore, this also shows that GSH does not affect LPS or
surface receptors on the extracellular membrane. Increases in
cellular thiol status have previously been shown to block NF-kB,
MAP kinase, and phosphatase activity as well, also pointing to an
intracellular effect rather than an extracellular one
[31,32,33,34,35]. While the mechanism by which thiol status
attenuates inflammation is not exactly clear, several theories have
been proposed. There is some suggestion that thiols protect redox
sensitive phosphatases or modulate kinase activation, resulting in
modulated NF-kB activity [36]. There is also some evidence that
GSH may be detoxifying hydrogen peroxide and other ROS
produced from membrane associated NADPH oxidase enzymes,
thus preventing the downstream signaling events that lead to
activation of certain proinflammatory pathways [37,38]. While the
detoxification of ROS would certainly fit with the antioxidant
properties of GSH, not all inflammatory stimuli have a large ROS
component. For instance, certain activators like PMA have been
shown to cause an increase in ROS [20], while others such as LPS
used in the current study are not typically associated with large
increases in ROS [39]. Additionally, in the current study, LPS did
not have any effect on intracellular levels of GSH, which would
not be expected if there was a large ROS component to the
activation. Therefore, while the intracellular GSH status is the
critical component to the modulation of inflammation, it is still not
exactly clear how GSH prevents the activation of NF-kB.
The fact that the intracellular GSH status is important for the
modulation of GSH provides an interesting dynamic, especially in
the lung. It is well known the ELF GSH is maintained at much
higher levels than the corresponding plasma GSH [5], but there
has really been very rationale little to explain this. Previously,
GSH was seen mainly as a defense mechanism against the high
oxygen tension and potential oxidative stress from inhaled gases,
particulates, and pathogens in the lung. The current study would
suggest an inter-relationship between the epithelial cells, which
supply the bulk of the ELF GSH, and the resident AMs that can
utilize that GSH. The reliance of the macrophages on the GSH
that is supplied by the epithelial cells indicates another role for
GSH in the ELF. For instance, modulating ELF GSH levels could
lead to modulating the response to certain inflammatory stimuli.
While inflammatory signaling is an important part of the immune
system in many lung diseases this signaling system becomes
dysregulated and prolonged which contributes to the progression
of lung diseases [24,40]. The triggers that either prevent or
exacerbate inflammatory signals are numerous and the current
studies suggest GSH status of the airway may be an important
aspect in its regulation.
There are numerous lung diseases with dysregulated ELF GSH,
such as cystic fibrosis (CF), acute respiratory distress syndrome
(ARDS), idiopathic pulmonary fibrosis (IPF), or aging [5]. Many of
these diseases are also associated with increased or exaggerated
inflammatory responses and one could postulate that it may be the
altered macrophage GSH status that could be contributing to the
dysregulated inflammation. One of the more interesting aspects of
the potential contribution to diseases might be with CF. With CF
mutations the apical transport of GSH is altered, which decreases
ELF GSH levels, but in theory that should not affect the
intracellular levels of macrophages, and yet the macrophage
GSH levels are decreased as much as all of the other models
examined. Furthermore, macrophages have been implicated in
promoting the progression of CF [26,41,42]. This could suggest
that finding ways to alter ELF GSH levels in inflammatory lung
diseases like CF or COPD, one could potentially regulate
inflammatory responses with the goal to slow or prevent the
progression of inflammatory lung diseases. Although a few clinical
trials of inhaled GSH have been done in CF subjects, the results
have been only modestly positive [43,44]. A potential problem
with inhalation delivery of GSH is the large amount of oxidation
that is reported to occur which may limit the amount of the active
reduced form of GSH in the ELF [45]. New therapeutic
approaches that stimulate lung epithelial cells to secrete the active
Macropinocytosis of GSH Attenuates Inflammation
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25704reduced form of GSH directly into the ELF will be needed to
overcome this obstacle. We have recently reported that hypertonic
saline nebulization increases ELF GSH by this type of mechanism
[46]. These types of therapeutic approaches may provide effective
therapeutic options for a whole host of lung disease associated with
low ELF GSH levels including COPD, lung fibrosis, ARDS and
CF.
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